The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Biological Vaccines Adjuvants Market Research Report 2024

Global Biological Vaccines Adjuvants Market Research Report 2024

Publishing Date : Oct, 2022

License Type :
 

Report Code : 1722177

No of Pages : 115

Ask Your Query

Synopsis
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years.
The global Biological Vaccines Adjuvants market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
The major global manufacturers of Biological Vaccines Adjuvants include GSK, Dynavax Technologies, Novavax, Agenus, Croda International, Seppic, OZ Biosciences, Phibro Animal Health Corporation and Associated British Foods, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Aluminum Adjuvant, which accounted for % of the global market of Biological Vaccines Adjuvants in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Biological Vaccines Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Vaccines Adjuvants.
The Biological Vaccines Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Biological Vaccines Adjuvants market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biological Vaccines Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Some of the prominent players reviewed in the research report include:

  • GSK
  • Dynavax Technologies
  • Novavax
  • Agenus
  • Croda International
  • Seppic
  • OZ Biosciences
  • Phibro Animal Health Corporation
  • Associated British Foods
  • InvivoGen
  • Merck KGaA
  • CSL Limited
  • Vertellus
  • Allergy Therapeutics
  • Riboxx GmbH
  • CaPtivatϵ Pharmaceuticals
  • EuBiologics
  • Pacific GeneTech
  • Hawaii Biotech
  • Vaxine Pty Ltd.
  • Creative Diagnostics
  • LiteVax BV
  • Mukta Industries
  • Oncovir
  • TiterMax USA

Product Type Insights
Global markets are presented by Biological Vaccines Adjuvants type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Biological Vaccines Adjuvants are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).

Biological Vaccines Adjuvants segment by Type

  • Aluminum Adjuvant
  • Emulsions Adjuvant
  • Others

Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Biological Vaccines Adjuvants market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Biological Vaccines Adjuvants market.

Biological Vaccines Adjuvants segment by Application

  • Human Vaccine
  • Veterinary Vaccine

Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia) 
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Biological Vaccines Adjuvants market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

  • This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biological Vaccines Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
  • This report will help stakeholders to understand the global industry status and trends of Biological Vaccines Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.
  • This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
  • This report stays updated with novel technology integration, features, and the latest developments in the market
  • This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Biological Vaccines Adjuvants industry.
  • This report helps stakeholders to gain insights into which regions to target globally
  • This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biological Vaccines Adjuvants.
  • This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biological Vaccines Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biological Vaccines Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.

Index

1 Biological Vaccines Adjuvants Market Overview
1.1 Product Overview and Scope of Biological Vaccines Adjuvants
1.2 Biological Vaccines Adjuvants Segment by Type
1.2.1 Global Biological Vaccines Adjuvants Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Aluminum Adjuvant
1.2.3 Emulsions Adjuvant
1.2.4 Others
1.3 Biological Vaccines Adjuvants Segment by Application
1.3.1 Global Biological Vaccines Adjuvants Sales Comparison by Application: (2022-2028)
1.3.2 Human Vaccine
1.3.3 Veterinary Vaccine
1.4 Global Biological Vaccines Adjuvants Market Size Estimates and Forecasts
1.4.1 Global Biological Vaccines Adjuvants Revenue 2017-2028
1.4.2 Global Biological Vaccines Adjuvants Sales 2017-2028
1.4.3 Biological Vaccines Adjuvants Market Size by Region: 2017 Versus 2021 Versus 2028
2 Biological Vaccines Adjuvants Market Competition by Manufacturers
2.1 Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2017-2022)
2.2 Global Biological Vaccines Adjuvants Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Biological Vaccines Adjuvants Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Biological Vaccines Adjuvants Manufacturing Sites, Area Served, Product Type
2.5 Biological Vaccines Adjuvants Market Competitive Situation and Trends
2.5.1 Biological Vaccines Adjuvants Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biological Vaccines Adjuvants Players Market Share by Revenue
2.5.3 Global Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biological Vaccines Adjuvants Retrospective Market Scenario by Region
3.1 Global Biological Vaccines Adjuvants Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Biological Vaccines Adjuvants Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Biological Vaccines Adjuvants Market Facts & Figures by Country
3.3.1 North America Biological Vaccines Adjuvants Sales by Country
3.3.2 North America Biological Vaccines Adjuvants Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Biological Vaccines Adjuvants Market Facts & Figures by Country
3.4.1 Europe Biological Vaccines Adjuvants Sales by Country
3.4.2 Europe Biological Vaccines Adjuvants Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biological Vaccines Adjuvants Market Facts & Figures by Region
3.5.1 Asia Pacific Biological Vaccines Adjuvants Sales by Region
3.5.2 Asia Pacific Biological Vaccines Adjuvants Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Biological Vaccines Adjuvants Market Facts & Figures by Country
3.6.1 Latin America Biological Vaccines Adjuvants Sales by Country
3.6.2 Latin America Biological Vaccines Adjuvants Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Biological Vaccines Adjuvants Market Facts & Figures by Country
3.7.1 Middle East and Africa Biological Vaccines Adjuvants Sales by Country
3.7.2 Middle East and Africa Biological Vaccines Adjuvants Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Biological Vaccines Adjuvants Historic Market Analysis by Type
4.1 Global Biological Vaccines Adjuvants Sales Market Share by Type (2017-2022)
4.2 Global Biological Vaccines Adjuvants Revenue Market Share by Type (2017-2022)
4.3 Global Biological Vaccines Adjuvants Price by Type (2017-2022)
5 Global Biological Vaccines Adjuvants Historic Market Analysis by Application
5.1 Global Biological Vaccines Adjuvants Sales Market Share by Application (2017-2022)
5.2 Global Biological Vaccines Adjuvants Revenue Market Share by Application (2017-2022)
5.3 Global Biological Vaccines Adjuvants Price by Application (2017-2022)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.1.4 GSK Biological Vaccines Adjuvants Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Dynavax Technologies
6.2.1 Dynavax Technologies Corporation Information
6.2.2 Dynavax Technologies Description and Business Overview
6.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Dynavax Technologies Biological Vaccines Adjuvants Product Portfolio
6.2.5 Dynavax Technologies Recent Developments/Updates
6.3 Novavax
6.3.1 Novavax Corporation Information
6.3.2 Novavax Description and Business Overview
6.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Novavax Biological Vaccines Adjuvants Product Portfolio
6.3.5 Novavax Recent Developments/Updates
6.4 Agenus
6.4.1 Agenus Corporation Information
6.4.2 Agenus Description and Business Overview
6.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Agenus Biological Vaccines Adjuvants Product Portfolio
6.4.5 Agenus Recent Developments/Updates
6.5 Croda International
6.5.1 Croda International Corporation Information
6.5.2 Croda International Description and Business Overview
6.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Croda International Biological Vaccines Adjuvants Product Portfolio
6.5.5 Croda International Recent Developments/Updates
6.6 Seppic
6.6.1 Seppic Corporation Information
6.6.2 Seppic Description and Business Overview
6.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Seppic Biological Vaccines Adjuvants Product Portfolio
6.6.5 Seppic Recent Developments/Updates
6.7 OZ Biosciences
6.6.1 OZ Biosciences Corporation Information
6.6.2 OZ Biosciences Description and Business Overview
6.6.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.4.4 OZ Biosciences Biological Vaccines Adjuvants Product Portfolio
6.7.5 OZ Biosciences Recent Developments/Updates
6.8 Phibro Animal Health Corporation
6.8.1 Phibro Animal Health Corporation Corporation Information
6.8.2 Phibro Animal Health Corporation Description and Business Overview
6.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolio
6.8.5 Phibro Animal Health Corporation Recent Developments/Updates
6.9 Associated British Foods
6.9.1 Associated British Foods Corporation Information
6.9.2 Associated British Foods Description and Business Overview
6.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Associated British Foods Biological Vaccines Adjuvants Product Portfolio
6.9.5 Associated British Foods Recent Developments/Updates
6.10 InvivoGen
6.10.1 InvivoGen Corporation Information
6.10.2 InvivoGen Description and Business Overview
6.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.10.4 InvivoGen Biological Vaccines Adjuvants Product Portfolio
6.10.5 InvivoGen Recent Developments/Updates
6.11 Merck KGaA
6.11.1 Merck KGaA Corporation Information
6.11.2 Merck KGaA Biological Vaccines Adjuvants Description and Business Overview
6.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Merck KGaA Biological Vaccines Adjuvants Product Portfolio
6.11.5 Merck KGaA Recent Developments/Updates
6.12 CSL Limited
6.12.1 CSL Limited Corporation Information
6.12.2 CSL Limited Biological Vaccines Adjuvants Description and Business Overview
6.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.12.4 CSL Limited Biological Vaccines Adjuvants Product Portfolio
6.12.5 CSL Limited Recent Developments/Updates
6.13 Vertellus
6.13.1 Vertellus Corporation Information
6.13.2 Vertellus Biological Vaccines Adjuvants Description and Business Overview
6.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Vertellus Biological Vaccines Adjuvants Product Portfolio
6.13.5 Vertellus Recent Developments/Updates
6.14 Allergy Therapeutics
6.14.1 Allergy Therapeutics Corporation Information
6.14.2 Allergy Therapeutics Biological Vaccines Adjuvants Description and Business Overview
6.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Product Portfolio
6.14.5 Allergy Therapeutics Recent Developments/Updates
6.15 Riboxx GmbH
6.15.1 Riboxx GmbH Corporation Information
6.15.2 Riboxx GmbH Biological Vaccines Adjuvants Description and Business Overview
6.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Riboxx GmbH Biological Vaccines Adjuvants Product Portfolio
6.15.5 Riboxx GmbH Recent Developments/Updates
6.16 CaPtivatϵ Pharmaceuticals
6.16.1 CaPtivatϵ Pharmaceuticals Corporation Information
6.16.2 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Description and Business Overview
6.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product Portfolio
6.16.5 CaPtivatϵ Pharmaceuticals Recent Developments/Updates
6.17 EuBiologics
6.17.1 EuBiologics Corporation Information
6.17.2 EuBiologics Biological Vaccines Adjuvants Description and Business Overview
6.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.17.4 EuBiologics Biological Vaccines Adjuvants Product Portfolio
6.17.5 EuBiologics Recent Developments/Updates
6.18 Pacific GeneTech
6.18.1 Pacific GeneTech Corporation Information
6.18.2 Pacific GeneTech Biological Vaccines Adjuvants Description and Business Overview
6.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Pacific GeneTech Biological Vaccines Adjuvants Product Portfolio
6.18.5 Pacific GeneTech Recent Developments/Updates
6.19 Hawaii Biotech
6.19.1 Hawaii Biotech Corporation Information
6.19.2 Hawaii Biotech Biological Vaccines Adjuvants Description and Business Overview
6.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Hawaii Biotech Biological Vaccines Adjuvants Product Portfolio
6.19.5 Hawaii Biotech Recent Developments/Updates
6.20 Vaxine Pty Ltd.
6.20.1 Vaxine Pty Ltd. Corporation Information
6.20.2 Vaxine Pty Ltd. Biological Vaccines Adjuvants Description and Business Overview
6.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolio
6.20.5 Vaxine Pty Ltd. Recent Developments/Updates
6.21 Creative Diagnostics
6.21.1 Creative Diagnostics Corporation Information
6.21.2 Creative Diagnostics Biological Vaccines Adjuvants Description and Business Overview
6.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Creative Diagnostics Biological Vaccines Adjuvants Product Portfolio
6.21.5 Creative Diagnostics Recent Developments/Updates
6.22 LiteVax BV
6.22.1 LiteVax BV Corporation Information
6.22.2 LiteVax BV Biological Vaccines Adjuvants Description and Business Overview
6.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.22.4 LiteVax BV Biological Vaccines Adjuvants Product Portfolio
6.22.5 LiteVax BV Recent Developments/Updates
6.23 Mukta Industries
6.23.1 Mukta Industries Corporation Information
6.23.2 Mukta Industries Biological Vaccines Adjuvants Description and Business Overview
6.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Mukta Industries Biological Vaccines Adjuvants Product Portfolio
6.23.5 Mukta Industries Recent Developments/Updates
6.24 Oncovir
6.24.1 Oncovir Corporation Information
6.24.2 Oncovir Biological Vaccines Adjuvants Description and Business Overview
6.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Oncovir Biological Vaccines Adjuvants Product Portfolio
6.24.5 Oncovir Recent Developments/Updates
6.25 TiterMax USA
6.25.1 TiterMax USA Corporation Information
6.25.2 TiterMax USA Biological Vaccines Adjuvants Description and Business Overview
6.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2017-2022)
6.25.4 TiterMax USA Biological Vaccines Adjuvants Product Portfolio
6.25.5 TiterMax USA Recent Developments/Updates
7 Biological Vaccines Adjuvants Manufacturing Cost Analysis
7.1 Biological Vaccines Adjuvants Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biological Vaccines Adjuvants
7.4 Biological Vaccines Adjuvants Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biological Vaccines Adjuvants Distributors List
8.3 Biological Vaccines Adjuvants Customers
9 Biological Vaccines Adjuvants Market Dynamics
9.1 Biological Vaccines Adjuvants Industry Trends
9.2 Biological Vaccines Adjuvants Market Drivers
9.3 Biological Vaccines Adjuvants Market Challenges
9.4 Biological Vaccines Adjuvants Market Restraints
10 Global Market Forecast
10.1 Biological Vaccines Adjuvants Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biological Vaccines Adjuvants by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Biological Vaccines Adjuvants by Type (2023-2028)
10.2 Biological Vaccines Adjuvants Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biological Vaccines Adjuvants by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Biological Vaccines Adjuvants by Application (2023-2028)
10.3 Biological Vaccines Adjuvants Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biological Vaccines Adjuvants by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Biological Vaccines Adjuvants by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Biological Vaccines Adjuvants Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Biological Vaccines Adjuvants Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Biological Vaccines Adjuvants Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Biological Vaccines Adjuvants Market Competitive Situation by Manufacturers in 2021
Table 5. Global Biological Vaccines Adjuvants Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Biological Vaccines Adjuvants Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Biological Vaccines Adjuvants Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Biological Vaccines Adjuvants Manufacturing Sites and Area Served
Table 11. Manufacturers Biological Vaccines Adjuvants Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Biological Vaccines Adjuvants by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biological Vaccines Adjuvants as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Biological Vaccines Adjuvants Sales by Region (2017-2022) & (K Units)
Table 16. Global Biological Vaccines Adjuvants Sales Market Share by Region (2017-2022)
Table 17. Global Biological Vaccines Adjuvants Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Biological Vaccines Adjuvants Revenue Market Share by Region (2017-2022)
Table 19. North America Biological Vaccines Adjuvants Sales by Country (2017-2022) & (K Units)
Table 20. North America Biological Vaccines Adjuvants Sales Market Share by Country (2017-2022)
Table 21. North America Biological Vaccines Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Biological Vaccines Adjuvants Revenue Market Share by Country (2017-2022)
Table 23. Europe Biological Vaccines Adjuvants Sales by Country (2017-2022) & (K Units)
Table 24. Europe Biological Vaccines Adjuvants Sales Market Share by Country (2017-2022)
Table 25. Europe Biological Vaccines Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Biological Vaccines Adjuvants Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Biological Vaccines Adjuvants Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Biological Vaccines Adjuvants Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Biological Vaccines Adjuvants Revenue Market Share by Region (2017-2022)
Table 31. Latin America Biological Vaccines Adjuvants Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Biological Vaccines Adjuvants Sales Market Share by Country (2017-2022)
Table 33. Latin America Biological Vaccines Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Biological Vaccines Adjuvants Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Biological Vaccines Adjuvants Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Biological Vaccines Adjuvants Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Biological Vaccines Adjuvants Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Biological Vaccines Adjuvants Revenue Market Share by Country (2017-2022)
Table 39. Global Biological Vaccines Adjuvants Sales by Type (2017-2022) & (K Units)
Table 40. Global Biological Vaccines Adjuvants Sales Market Share by Type (2017-2022)
Table 41. Global Biological Vaccines Adjuvants Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Biological Vaccines Adjuvants Revenue Share by Type (2017-2022)
Table 43. Global Biological Vaccines Adjuvants Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Biological Vaccines Adjuvants Sales (K Units) by Application (2017-2022)
Table 45. Global Biological Vaccines Adjuvants Sales Market Share by Application (2017-2022)
Table 46. Global Biological Vaccines Adjuvants Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Biological Vaccines Adjuvants Revenue Share by Application (2017-2022)
Table 48. Global Biological Vaccines Adjuvants Price by Application (2017-2022) & (US$/Unit)
Table 49. GSK Corporation Information
Table 50. GSK Description and Business Overview
Table 51. GSK Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. GSK Biological Vaccines Adjuvants Product
Table 53. GSK Recent Developments/Updates
Table 54. Dynavax Technologies Corporation Information
Table 55. Dynavax Technologies Description and Business Overview
Table 56. Dynavax Technologies Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Dynavax Technologies Biological Vaccines Adjuvants Product
Table 58. Dynavax Technologies Recent Developments/Updates
Table 59. Novavax Corporation Information
Table 60. Novavax Description and Business Overview
Table 61. Novavax Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Novavax Biological Vaccines Adjuvants Product
Table 63. Novavax Recent Developments/Updates
Table 64. Agenus Corporation Information
Table 65. Agenus Description and Business Overview
Table 66. Agenus Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Agenus Biological Vaccines Adjuvants Product
Table 68. Agenus Recent Developments/Updates
Table 69. Croda International Corporation Information
Table 70. Croda International Description and Business Overview
Table 71. Croda International Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Croda International Biological Vaccines Adjuvants Product
Table 73. Croda International Recent Developments/Updates
Table 74. Seppic Corporation Information
Table 75. Seppic Description and Business Overview
Table 76. Seppic Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Seppic Biological Vaccines Adjuvants Product
Table 78. Seppic Recent Developments/Updates
Table 79. OZ Biosciences Corporation Information
Table 80. OZ Biosciences Description and Business Overview
Table 81. OZ Biosciences Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. OZ Biosciences Biological Vaccines Adjuvants Product
Table 83. OZ Biosciences Recent Developments/Updates
Table 84. Phibro Animal Health Corporation Corporation Information
Table 85. Phibro Animal Health Corporation Description and Business Overview
Table 86. Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Phibro Animal Health Corporation Biological Vaccines Adjuvants Product
Table 88. Phibro Animal Health Corporation Recent Developments/Updates
Table 89. Associated British Foods Corporation Information
Table 90. Associated British Foods Description and Business Overview
Table 91. Associated British Foods Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Associated British Foods Biological Vaccines Adjuvants Product
Table 93. Associated British Foods Recent Developments/Updates
Table 94. InvivoGen Corporation Information
Table 95. InvivoGen Description and Business Overview
Table 96. InvivoGen Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. InvivoGen Biological Vaccines Adjuvants Product
Table 98. InvivoGen Recent Developments/Updates
Table 99. Merck KGaA Corporation Information
Table 100. Merck KGaA Description and Business Overview
Table 101. Merck KGaA Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Merck KGaA Biological Vaccines Adjuvants Product
Table 103. Merck KGaA Recent Developments/Updates
Table 104. CSL Limited Corporation Information
Table 105. CSL Limited Description and Business Overview
Table 106. CSL Limited Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 107. CSL Limited Biological Vaccines Adjuvants Product
Table 108. CSL Limited Recent Developments/Updates
Table 109. Vertellus Corporation Information
Table 110. Vertellus Description and Business Overview
Table 111. Vertellus Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 112. Vertellus Biological Vaccines Adjuvants Product
Table 113. Vertellus Recent Developments/Updates
Table 114. Allergy Therapeutics Corporation Information
Table 115. Allergy Therapeutics Description and Business Overview
Table 116. Allergy Therapeutics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 117. Allergy Therapeutics Biological Vaccines Adjuvants Product
Table 118. Allergy Therapeutics Recent Developments/Updates
Table 119. Riboxx GmbH Corporation Information
Table 120. Riboxx GmbH Description and Business Overview
Table 121. Riboxx GmbH Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 122. Riboxx GmbH Biological Vaccines Adjuvants Product
Table 123. Riboxx GmbH Recent Developments/Updates
Table 124. CaPtivatϵ Pharmaceuticals Corporation Information
Table 125. CaPtivatϵ Pharmaceuticals Description and Business Overview
Table 126. CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 127. CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product
Table 128. CaPtivatϵ Pharmaceuticals Recent Developments/Updates
Table 129. EuBiologics Corporation Information
Table 130. EuBiologics Description and Business Overview
Table 131. EuBiologics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 132. EuBiologics Biological Vaccines Adjuvants Product
Table 133. EuBiologics Recent Developments/Updates
Table 134. Pacific GeneTech Corporation Information
Table 135. Pacific GeneTech Description and Business Overview
Table 136. Pacific GeneTech Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 137. Pacific GeneTech Biological Vaccines Adjuvants Product
Table 138. Pacific GeneTech Recent Developments/Updates
Table 139. Hawaii Biotech Corporation Information
Table 140. Hawaii Biotech Description and Business Overview
Table 141. Hawaii Biotech Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 142. Hawaii Biotech Biological Vaccines Adjuvants Product
Table 143. Hawaii Biotech Recent Developments/Updates
Table 144. Vaxine Pty Ltd. Corporation Information
Table 145. Vaxine Pty Ltd. Description and Business Overview
Table 146. Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 147. Vaxine Pty Ltd. Biological Vaccines Adjuvants Product
Table 148. Vaxine Pty Ltd. Recent Developments/Updates
Table 149. Creative Diagnostics Corporation Information
Table 150. Creative Diagnostics Description and Business Overview
Table 151. Creative Diagnostics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 152. Creative Diagnostics Biological Vaccines Adjuvants Product
Table 153. Creative Diagnostics Recent Developments/Updates
Table 154. LiteVax BV Corporation Information
Table 155. LiteVax BV Description and Business Overview
Table 156. LiteVax BV Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 157. LiteVax BV Biological Vaccines Adjuvants Product
Table 158. LiteVax BV Recent Developments/Updates
Table 159. Mukta Industries Corporation Information
Table 160. Mukta Industries Description and Business Overview
Table 161. Mukta Industries Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 162. Mukta Industries Biological Vaccines Adjuvants Product
Table 163. Mukta Industries Recent Developments/Updates
Table 164. Oncovir Corporation Information
Table 165. Oncovir Description and Business Overview
Table 166. Oncovir Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 167. Oncovir Biological Vaccines Adjuvants Product
Table 168. Oncovir Recent Developments/Updates
Table 169. TiterMax USA Corporation Information
Table 170. TiterMax USA Description and Business Overview
Table 171. TiterMax USA Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 172. TiterMax USA Biological Vaccines Adjuvants Product
Table 173. TiterMax USA Recent Developments/Updates
Table 174. Production Base and Market Concentration Rate of Raw Material
Table 175. Key Suppliers of Raw Materials
Table 176. Biological Vaccines Adjuvants Distributors List
Table 177. Biological Vaccines Adjuvants Customers List
Table 178. Biological Vaccines Adjuvants Market Trends
Table 179. Biological Vaccines Adjuvants Market Drivers
Table 180. Biological Vaccines Adjuvants Market Challenges
Table 181. Biological Vaccines Adjuvants Market Restraints
Table 182. Global Biological Vaccines Adjuvants Sales Forecast by Type (2023-2028) & (K Units)
Table 183. Global Biological Vaccines Adjuvants Sales Market Share Forecast by Type (2023-2028)
Table 184. Global Biological Vaccines Adjuvants Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 185. Global Biological Vaccines Adjuvants Revenue Market Share Forecast by Type (2023-2028)
Table 186. Global Biological Vaccines Adjuvants Sales Forecast by Application (2023-2028) & (K Units)
Table 187. Global Biological Vaccines Adjuvants Sales Market Share Forecast by Application (2023-2028)
Table 188. Global Biological Vaccines Adjuvants Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 189. Global Biological Vaccines Adjuvants Revenue Market Share Forecast by Application (2023-2028)
Table 190. Global Biological Vaccines Adjuvants Sales Forecast by Region (2023-2028) & (K Units)
Table 191. Global Biological Vaccines Adjuvants Sales Market Share Forecast by Region (2023-2028)
Table 192. Global Biological Vaccines Adjuvants Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 193. Global Biological Vaccines Adjuvants Revenue Market Share Forecast by Region (2023-2028)
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biological Vaccines Adjuvants
Figure 2. Global Biological Vaccines Adjuvants Market Share by Type in 2021 & 2028
Figure 3. Aluminum Adjuvant Product Picture
Figure 4. Emulsions Adjuvant Product Picture
Figure 5. Others Product Picture
Figure 6. Global Biological Vaccines Adjuvants Market Share by Application in 2021 & 2028
Figure 7. Human Vaccine
Figure 8. Veterinary Vaccine
Figure 9. Global Biological Vaccines Adjuvants Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Biological Vaccines Adjuvants Market Size (2017-2028) & (US$ Million)
Figure 11. Global Biological Vaccines Adjuvants Sales (2017-2028) & (K Units)
Figure 12. Biological Vaccines Adjuvants Sales Share by Manufacturers in 2021
Figure 13. Global Biological Vaccines Adjuvants Revenue Share by Manufacturers in 2021
Figure 14. The Global 5 and 10 Largest Biological Vaccines Adjuvants Players: Market Share by Revenue in 2021
Figure 15. Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 16. Global Biological Vaccines Adjuvants Sales Market Share by Region (2017-2022)
Figure 17. Global Biological Vaccines Adjuvants Sales Market Share by Region in 2021
Figure 18. Global Biological Vaccines Adjuvants Revenue Market Share by Region (2017-2022)
Figure 19. Global Biological Vaccines Adjuvants Revenue Market Share by Region in 2021
Figure 20. United States Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Canada Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Germany Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. France Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. U.K. Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Italy Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Russia Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. China Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Japan Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. South Korea Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. India Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Australia Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. China Taiwan Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Indonesia Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Thailand Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Malaysia Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Mexico Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Brazil Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Argentina Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Colombia Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Turkey Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Saudi Arabia Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. UAE Biological Vaccines Adjuvants Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Sales Market Share of Biological Vaccines Adjuvants by Type (2017-2022)
Figure 44. Manufacturing Cost Structure of Biological Vaccines Adjuvants
Figure 45. Manufacturing Process Analysis of Biological Vaccines Adjuvants
Figure 46. Biological Vaccines Adjuvants Industrial Chain Analysis
Figure 47. Channels of Distribution
Figure 48. Distributors Profiles
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Latest Life Science Market Reports

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock